Skip to main content

Table 2 Results of cMap analysis based on risk difference genes

From: Construction of ceRNA prognostic model based on the CCR7/CCL19 chemokine axis as a biomarker in breast cancer

cMap name

mean

n

enrichment

p

specificity

percent non-null

Convolamine

-0.573

4

-0.888

0.00036

0

75

Amikacin

0.465

4

0.864

0.00046

0.0089

75

AH-23,848

-0.76

3

-0.933

0.00048

0

100

Ondansetron

-0.442

4

-0.835

0.00133

0

50

Flucloxacillin

-0.412

4

-0.823

0.00189

0.0063

50